Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
Eric L. Simpson, Jonathan I. Silverberg, Audrey Nosbaum, et al.
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 5, pp. 693-707
Open Access | Times Cited: 102

Showing 1-25 of 102 citing articles:

European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
Andreas Wollenberg, Maria Kinberger, B.W.M. Arents, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 9, pp. 1409-1431
Open Access | Times Cited: 251
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue Chen, Qinfan Yao, Xinyu Gu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 226
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial
Kristian Reich, Jacob P. Thyssen, Andrew Blauvelt, et al.
The Lancet (2022) Vol. 400, Iss. 10348, pp. 273-282
Closed Access | Times Cited: 154
JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
I‐Hsin Huang, Yi‐Teng Hung, Po‐Chien Wu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 140
Protein kinases: drug targets for immunological disorders
Leslie Castelo‐Soccio, Hanna Kim, Massimo Gadina, et al.
Nature reviews. Immunology (2023) Vol. 23, Iss. 12, pp. 787-806
Open Access | Times Cited: 57
Expert consensus on the systemic treatment of atopic dermatitis in special populations
David N. Adam, Melinda Gooderham, Jennifer Beecker, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 6, pp. 1135-1148
Open Access | Times Cited: 53
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Svenja Müller, Laura Maintz, Thomas Bieber
Allergy (2024) Vol. 79, Iss. 6, pp. 1501-1515
Open Access | Times Cited: 49
Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence
Masahiro Kamata, Yayoi Tada
JID Innovations (2023) Vol. 3, Iss. 3, pp. 100195-100195
Open Access | Times Cited: 44
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 2, pp. 299-314
Open Access | Times Cited: 20
Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors
Richard W. Kim, Megan Lam, Katrina Abuabara, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 2, pp. 179-193
Closed Access | Times Cited: 19
Atopic dermatitis
Emma Guttman‐Yassky, Yael Renert‐Yuval, Patrick M. Brunner
The Lancet (2025) Vol. 405, Iss. 10478, pp. 583-596
Closed Access | Times Cited: 3
Abrocitinib: First Approval
Emma D. Deeks, Sean T. Duggan
Drugs (2021) Vol. 81, Iss. 18, pp. 2149-2157
Open Access | Times Cited: 91
Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors
Tai‐Li Chen, Ling-Ling Lee, Huei‐Kai Huang, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 11, pp. 1254-1254
Open Access | Times Cited: 45
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies
Emma Guttman‐Yassky, Jacob P. Thyssen, Jonathan I. Silverberg, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 151, Iss. 1, pp. 172-181
Open Access | Times Cited: 40
JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety
Sarina B. Elmariah, Jeffrey S. Smith, Joseph F. Merola
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 4, pp. 427-431
Closed Access | Times Cited: 39
Oral Janus kinase inhibitors for atopic dermatitis
Daniela Mikhaylov, Benjamin Ungar, Yael Renert‐Yuval, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 130, Iss. 5, pp. 577-592
Open Access | Times Cited: 37
Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases
Peter C. Taylor, Ernest Choy, Xenofon Baraliakos, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 2, pp. 298-308
Open Access | Times Cited: 32
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
Helena Iznardo, Esther Roé, E. Serra‐Baldrich, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 385-385
Open Access | Times Cited: 23
Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors
Patrick A. Ireland, Nicholas Jansson, Sascha Spencer, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 3, pp. 281-281
Closed Access | Times Cited: 10
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure
Eric L. Simpson, Jonathan I. Silverberg, Audrey Nosbaum, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 4, pp. 639-654
Open Access | Times Cited: 9
Infections in Patients with Atopic Dermatitis and the Influence of Treatment
Maddalena Napolitano, Maria Esposito, Maria Concetta Fargnoli, et al.
American Journal of Clinical Dermatology (2025)
Open Access | Times Cited: 1
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement
Victoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases (2025)
Open Access | Times Cited: 1
Flavonoids as Natural Anti-Inflammatory Agents in the Atopic Dermatitis Treatment
Nik Khairunissa Nik Abdullah Zawawi, Haslina Ahmad, Rajesh Madatheri, et al.
Pharmaceutics (2025) Vol. 17, Iss. 2, pp. 261-261
Open Access | Times Cited: 1
Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis
Patrick O. Perche, Madison K. Cook, Steven R. Feldman
Annals of Pharmacotherapy (2022) Vol. 57, Iss. 1, pp. 86-98
Closed Access | Times Cited: 36
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials
Thomas Bieber, Norito Katoh, Eric L. Simpson, et al.
Journal of Dermatological Treatment (2022) Vol. 34, Iss. 1
Open Access | Times Cited: 32
Page 1 - Next Page

Scroll to top